CA3254966A1 — PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A]PYRROLO[2,3-E]PYRAZINE-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND RELATED SOLID FORMS
Assigned to AbbVie Inc · Expires 2025-04-12 · 1y expired
What this patent protects
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[l,2- a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-l-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including …
USPTO Abstract
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[l,2- a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-l-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Drugs covered by this patent
- Rinvoq (upadacitinib) · AbbVie Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.